Home › NDC Lookup › Ingredients › Erythromycin And Benzoyl Peroxide › 68682-0901-46
Erythromycin and Benzoyl Peroxide Kit — NDC 68682-0901-46 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Erythromycin and Benzoyl Peroxide Kit — NDC 68682-901-46 (Billing 68682-0901-46)

by Oceanside Pharmaceuticals · 1 KIT in 1 CARTON * 40 g in 1 JAR * 1.6 g in 1 VIAL, PLASTIC

This is a package of Erythromycin and Benzoyl Peroxide Kit from Oceanside Pharmaceuticals, marketed since Oct 1984 and currently FDA-listed; retail pharmacies pay about $1.08 per g (NADAC). It is this product's only package size.

NDC 68682-0901-46
🏷️ FDA NDC (as labeled) 68682-901-46 billing pads the product segment with a zero
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 68682-901-46 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
68682 labeler · 901 product · 46 package
Package marketed since
Oct 26, 1984
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 6868290146 7
Medicaid fills, this package
6,795 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 68682-901-46
Product NDC 68682-901
11-digit billing NDC 68682090146
NCPDP billing unit GM — per gram (weight)
RxCUI 244374, 308694
Application # NDA050557
SPL Set ID be5bce27-bbb7-4503-b609-d89a77ee1e05
DEA schedule Non-controlled
Marketing category NDA AUTHORIZED GENERIC
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1984-10-26
Dosage form KIT
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90059902104010
GPI class Benzoyl Peroxide-Erythromycin
GCN Seq No 007678
GCN 85400
HICL code 003354
Ingredient (HICL) Erythromycin/Benzoyl Peroxide
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5W
Therapeutic class — specific (HIC3) Topical Antibiotics
AHFS code 08:12.12.04
AHFS class Erythromycin Antibiotics
FDB label name ERYTHROMYCIN-BENZOYL GEL
FDB brand name Erythromycin-Benzoyl Peroxide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007678
  • GCN: 85400
  • GPI-14 (Medi-Span): 90059902104010
  • HICL (First Databank): 003354
  • AHFS class code: 08:12.12.04
  • RxCUI (RxNorm): 244374
Why two NDCs? The FDA registers this code as 68682-901-46 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 68682-0901-46. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Peroxides class.

Drug family (ATC) Peroxides
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name ERYTHROMYCIN-BENZOYL GEL Ingredient Erythromycin/Benzoyl Peroxide
📖 What it is MedlinePlus · NLM

The combination of erythromycin and benzoyl peroxide is used to treat acne. Erythromycin and benzoyl peroxide are in a class of medications called topical antibiotics. The combination of erythromycin and benzoyl peroxide works by killing the bacteria that cause acne.

Read the full MedlinePlus article ↗

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $1.078 —
Medicaid paysCMS SDUD · 12 mo $1.14 —
Medicare drug plans payPart D · Q2 2026 $1.57 —
NADAC price history (per g) — tap or hover for the price & month
Dec 2021 Apr 2022 Sep 2022 Feb 2024 $1.191 $0.752
▼ Down 4% over the last 15 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
68682-0901-46 You're viewing this Main listing 1 KIT in 1 CARTON * 40 g in 1 JAR * 1.6 g in 1 VIAL, PLASTIC 1984-10-26 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Erythromycin and Benzoyl Peroxidethis 68682-0901-46 Oceanside 1 kit $1.078 AB FDA listed —
Erythromycin and Benzoyl Peroxide 68682-0900-23 Oceanside 1 kit $1.593 AB FDA listed +48%
Erythromycin and Benzoyl Peroxide 30 mg/g; 50 mg/g 64980-0328-01 Rising 23.3 g $1.599 AB Availability likely +48%
Benzamycin 00187-5205-46 Bausch 1 kit — AB FDA listed —
About this product: this is an authorized generic — the brand-name product marketed without its brand name. Other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1984
On the market since
Oct 1984
📍
2026
Currently FDA-listed
42 years listed
🔒
·
Generic approved (availability unconfirmed)
see note
🔒Generic approved by FDA, but pharmacy availability is not confirmed

The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

A current SPL was checked, but it does not contain a structured or narrative inactive-ingredient list for this product. This does not mean the product has no inactive ingredients.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerOceanside Pharmaceuticals
Application holderVALEANT INTERNATIONAL SRL
FDA applicationNDA050557 (NDA AUTHORIZED GENERIC)
Labeler code68682
First marketedOct 1984
Product typeHuman Prescription Drug
Portfolio87 products on file

More NDCs from Oceanside Pharmaceuticals labeler code 68682

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 16 words ▾

INDICATIONS AND USAGE Erythromycin-Benzoyl Peroxide Topical Gel is indicated for the topical treatment of acne vulgaris.

⏱️ Dosage and Administration 38 words ▾

DOSAGE AND ADMINISTRATION Erythromycin-Benzoyl Peroxide Topical Gel should be applied twice daily, morning and evening, or as directed by a physician, to affected areas after the skin is thoroughly washed, rinsed with warm water and gently patted dry.

⛔ Contraindications 19 words ▾

CONTRAINDICATIONS Erythromycin-Benzoyl Peroxide Topical Gel is contraindicated in those individuals who have shown hypersensitivity to any of its components.

⚠️ Warnings 130 words ▾

WARNINGS Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia.

Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis.” After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C. difficile colitis.

🤒 Adverse Reactions 89 words ▾

ADVERSE REACTIONS In controlled clinical trials, the incidence of adverse reactions associated with the use of Erythromycin-Benzoyl Peroxide Topical Gel was approximately 3%. These were dryness and urticarial reaction. The following additional local adverse reactions have been reported occasionally: irritation of the skin including peeling, itching, burning sensation, erythema, inflammation of the face, eyes and nose, and irritation of the eyes.

Skin discoloration, oiliness and tenderness of the skin have also been reported. To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🤰 Pregnancy 108 words ▾

Pregnancy: Teratogenic Effects Animal reproduction studies have not been conducted with Erythromycin-Benzoyl Peroxide Topical Gel or benzoyl peroxide. There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% diet) prior to and during mating, during gestation and through weaning of two successive litters. There are no well-controlled trials in pregnant women with Erythromycin-Benzoyl Peroxide Topical Gel.

It also is not known whether Erythromycin-Benzoyl Peroxide Topical Gel can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Erythromycin-Benzoyl Peroxide Topical Gel should be given to a pregnant woman only if clearly needed.

🧒 Pediatric Use 20 words ▾

Pediatric Use: Safety and effectiveness of this product in pediatric patients below the age of 12 have not been established.

🧬 Clinical Pharmacology 148 words ▾

CLINICAL PHARMACOLOGY The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug. Benzoyl peroxide has a keratolytic and desquamative effect which may also contribute to its efficacy. Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid.

MICROBIOLOGY Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50 S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated in vitro between erythromycin, lincomycin, chloramphenicol and clindamycin. Benzoyl peroxide is an antibacterial agent which has been shown to be effective against Propionibacterium acnes, an anaerobe found in sebaceous follicles and comedones.

The antibacterial action of benzoyl peroxide is believed to be due to the release of active oxygen.

📦 How Supplied / Storage and Handling 154 words ▾

How Supplied and Compounding Directions: Size (Net Weight) NDC 68682- Benzoyl Peroxide Gel Active Erythromycin Powder (In Plastic Vial) 70% Ethyl Alcohol To Be Added 23.3 grams (as dispensed) 900-23 20 grams 0.8 grams 3 mL 46.6 grams (as dispensed) 901-46 40 grams 1.6 grams 6 mL Prior to dispensing, tap vial until all powder flows freely. Add indicated amount of room temperature 70% ethyl alcohol to vial (to the mark) and immediately shake to completely dissolve erythromycin . Add this solution to gel and stir until homogeneous in appearance (1 to 1½ minutes).

Erythromycin-Benzoyl Peroxide Topical Gel should then be stored under refrigeration. Do not freeze. Place a 3-month expiration date on the label.

NOTE: Prior to reconstitution, store at room temperature between 15° to 30°C (59° to 86°F). After reconstitution, store under refrigeration between 2° to 8°C (36° to 46°F). Do not freeze.

Keep tightly closed. Keep out of reach of children.

📦 Storage and Handling 39 words ▾

NOTE: Prior to reconstitution, store at room temperature between 15° to 30°C (59° to 86°F). After reconstitution, store under refrigeration between 2° to 8°C (36° to 46°F). Do not freeze. Keep tightly closed. Keep out of reach of children.

📋 Description 200 words ▾

DESCRIPTION Erythromycin-Benzoyl Peroxide Topical Gel contains erythromycin [(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-Dideoxy-3- C -methyl-3- O -methyl-α-L- ribo -hexopyranosyl)-oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D- xylo -hexopyranosyl]oxy] oxacyclotetradecane-2,10-dione]. Erythromycin is a macrolide antibiotic produced from a strain of Saccharopolyspora erythraea (formerly Streptomyces erythreus ). It is a base and readily forms salts with acids.

Chemically erythromycin is C 37 H 67 NO 13 . It has the following structural formula: Erythromycin has the molecular weight of 733.94. It is a white crystalline powder and has a solubility of approximately 1 mg/mL in water and is soluble in alcohol at 25°C.

Erythromycin-Benzoyl Peroxide Topical Gel also contains benzoyl peroxide for topical use. Benzoyl peroxide is an antibacterial and keratolytic agent. Chemically benzoyl peroxide is C 14 H 10 O 4 .

It has the following structural formula: Benzoyl peroxide has the molecular weight of 242.23. It is a white granular powder and is sparingly soluble in water and alcohol and soluble in acetone, chloroform and ether. Each gram of Erythromycin-Benzoyl Peroxide Topical Gel contains, as dispensed, 30 mg (3%) of erythromycin and 50 mg (5%) of benzoyl peroxide in a base of purified water USP, Carbomer Homopolymer Type C, alcohol 20%, sodium hydroxide NF, docusate sodium and fragrance.

Chemical Structure Chemical Structure

💬 Information for Patients 112 words ▾

Information for Patients: Patients using Erythromycin-Benzoyl Peroxide Topical Gel should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only.

Avoid contact with the eyes, nose, mouth, and all mucous membranes. 2. This medication should not be used for any disorder other than that for which it was prescribed.

3. Patients should not use any other topical acne preparation unless otherwise directed by their physician. 4.

Patients should report to their physician any signs of local adverse reactions. 5. Erythromycin-Benzoyl Peroxide Topical Gel may bleach hair or colored fabric.

6. Keep product refrigerated and discard after 3 months.

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General: For topical use only; not for ophthalmic use. Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating or abrasive agents. If severe irritation develops, discontinue use and institute appropriate therapy.

The use of antibiotic agents may be associated with the overgrowth of nonsusceptible organisms including fungi. If this occurs, discontinue use and take appropriate measures. Avoid contact with eyes and all mucous membranes.

Information for Patients: Patients using Erythromycin-Benzoyl Peroxide Topical Gel should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only.

Avoid contact with the eyes, nose, mouth, and all mucous membranes. 2. This medication should not be used for any disorder other than that for which it was prescribed.

3. Patients should not use any other topical acne preparation unless otherwise directed by their physician. 4.

Patients should report to their physician any signs of local adverse reactions. 5. Erythromycin-Benzoyl Peroxide Topical Gel may bleach hair or colored fabric.

6. Keep product refrigerated and discard after 3 months. CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY Data from a study using mice known to be highly susceptible to cancer suggests that benzoyl peroxide acts as a tumor promoter.

The clinical significance of this is unknown. No animal studies have been performed to evaluate the carcinogenic and mutagenic potential or effects on fertility of topical erythromycin. However, long-term (2-year) oral studies in rats with erythromycin ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity.

There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet. Pregnancy: Teratogenic Effects Animal reproduction studies have not been conducted with Erythromycin-Benzoyl Peroxide Topical Gel or benzoyl peroxide. There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% diet) prior to and during mating, during gestation and through weaning of two successive litters.

There are no well-controlled trials in pregnant women with Erythromycin-Benzoyl Peroxide Topical Gel. It also is not known whether Erythromycin-Benzoyl Peroxide Topical Gel can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Erythromycin-Benzoyl Peroxide Topical Gel should be given to a pregnant woman only if clearly needed.

Nursing Women: It is not known whether Erythromycin-Benzoyl Peroxide Topical Gel is excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing woman.

Pediatric Use: Safety and effectiveness of this product in pediatric patients below the age of 12 have not been established.

🍼 Nursing Mothers 45 words ▾

Nursing Women: It is not known whether Erythromycin-Benzoyl Peroxide Topical Gel is excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing woman.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 95 words ▾

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY Data from a study using mice known to be highly susceptible to cancer suggests that benzoyl peroxide acts as a tumor promoter. The clinical significance of this is unknown. No animal studies have been performed to evaluate the carcinogenic and mutagenic potential or effects on fertility of topical erythromycin.

However, long-term (2-year) oral studies in rats with erythromycin ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet.

📄 Package Label / Principal Display Panel 137 words ▾

PRINCIPAL DISPLAY PANEL - 46.6 gram Carton NDC 68682-901-46 Rx only Erythromycin-Benzoyl Peroxide Topical Gel FOR TOPICAL USE ONLY One 46.6 g Jar (as dispensed) OCEANSIDE PHARMACEUTICALS Carton 46.6 g gel.jpg

PRINCIPAL DISPLAY PANEL - 23.3 gram Carton NDC 68682-900-23 Rx only Erythromycin-Benzoyl Peroxide Topical Gel FOR TOPICAL USE ONLY One 23.3 g Jar (as dispensed) OCEANSIDE PHARMACEUTICALS Carton 23.3 g gel.jpg

PRINCIPAL DISPLAY PANEL - NDC 68682-924-08 Rx only Erythromycin Label 0.8 g erythromycin.jpg

Package/Label Display Panel NDC 68682-923-23 Rx only Erythromycin-Benzoyl Peroxide Topical Gel FOR TOPICAL USE ONLY One 23.3 g Jar (as dispensed) Label 23.3 g Jar.jpg

Package/Label Display Panel NDC 68682-925-16 Rx only Erythromycin Label 1.6 g erythromycin.jpg

Package/Label Display Panel NDC 68682-922-46 Rx only Erythromycin-Benzoyl Peroxide Topical Gel FOR TOPICAL USE ONLY One 46.6 g Jar (as dispensed) Label 46.6 g Jar.jpg

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
6.8K
Units reimbursed last 4 qtrs
317.6K
Gross reimbursed last 4 qtrs
$363.6K
Avg / prescription
$53.51
Avg / unit
$1.1447
Latest quarter Q4 2025
0Rx
Medicaid pays / g
$1.1447
gross reimbursed
vs
NADAC / g
$1.0776
acquisition cost
=
Spread
+$0.0671
+6% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
56% FFS 44% MCO
Fee-for-service · 3,812 Rx Managed care · 2,983 Rx
State Medicaid map
Alaska: no data reported AK Maine: 513 units · 36.8 per 100k residents ME Washington: 9,320 units · 119 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 1,118 units · 19.5 per 100k residents MN Wisconsin: no data reported WI Michigan: 9,600 units · 95.6 per 100k residents MI New York: 12,614 units · 64.5 per 100k residents NY Vermont: 3,542 units · 547 per 100k residents VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 48,463 units · 386 per 100k residents IL Indiana: 559 units · 8.1 per 100k residents IN Ohio: 14,353 units · 122 per 100k residents OH Pennsylvania: 7,129 units · 55.0 per 100k residents PA New Jersey: 3,961 units · 42.6 per 100k residents NJ Massachusetts: no data reported MA California: 159,830 units · 410 per 100k residents CA Utah: no data reported UT Colorado: 1,957 units · 33.3 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 7,548 units · 167 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: 3,542 units · 57.3 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: 15,331 units · 725 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: 12,722 units · 117 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: 1,911 units · 281 per 100k residents DC Hawaii: no data reported HI Texas: no data reported TX Florida: 3,588 units · 15.9 per 100k residents FL
Units reimbursed · per 100k residents
8.1725
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Mexico 725 /100k
2 Vermont 547 /100k
3 California 410 /100k
4 Illinois 386 /100k
5 D.C. 281 /100k
6 Kentucky 167 /100k
7 Ohio 122 /100k
8 Washington 119 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Erythromycin and Benzoyl Peroxide — the ingredient across all brands.

Top reported reactions

Inflammatory Bowel Disease18
Colitis Ulcerative15
Depression14
Anxiety11
Product Physical Consistency Issue11
Colitis10
Rash10

Age at onset

Adolescent2
Adult4
Elderly2

Reporter sex

162 reports
Male · 33%
Female · 65%
Unknown · 1%

Serious outcomes

Hospitalization31
Life-threatening5
Disabling5
Death4
Reports over time (by year) — tap or hover for the count & year
2020 2022 2024 2026 9 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product Kit / multi-component package

Kit / multi-component package

This NDC identifies a kit — a package containing more than one component. Structured data (pricing, ingredients, equivalents) is often reported per component rather than for the kit NDC itself, which can make this page look thinner than the components' own pages.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Oceanside Pharmaceuticals. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Oceanside Pharmaceuticals is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 68682-0900-23 · Oceanside 68682-0920-05 · Oceanside →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.